PTPN11 and neoplasm: These pathologies are more accentuated than with anti‐VEGF and anti‐Ang1/2 therapies (Scholz et al,2016), perhaps attributable to STAT activation as a consequence of SHP2 inhibition in the tumor vessels (Kreuzaler et al,2011; Salvucci et al,2015).